AIM ImmunoTech Inc. Gains 72.37%

AIM ImmunoTech Inc. (AIM:NYSEMKT) rocketted at $0.4, representing a gain of 72.4%. On Wed, May 27, 2026, AIM:NYSEMKT hit a New 2-Week Intraday High of $0.6. The stock appeared on our News Catalysts scanner on Wed, May 20, 2026 at 03:25 PM in the 'PRIVATE PLACEMENT' category. From Wed, May 13, 2026, the stock recorded 22.22% Up Days and 30.00% Green Days

The stock spiked on Mon, May 18, 2026 at $0.69 with a volume of 471M+.

About AIM ImmunoTech Inc. (AIM:NYSEMKT)

AIM ImmunoTech Inc is a US-based specialty pharmaceutical company. It is engaged in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune-based disorders. The products of the firm are Alferon N Injection and the experimental therapeutic Ampligen. Alferon N Injection is approved for a category of STD infection, and Ampligen represents a RNA being developed for viral diseases and disorders of the immune system. The sales revenue of the company is derived from the United States.